USD 0.0
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2021 | 51.7 Million USD | 166.54% |
2020 | 19.4 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2022 Q2 | 48.94 Million USD | 34.0% |
2022 Q1 | 36.52 Million USD | 0.0% |
2021 FY | 51.7 Million USD | 166.54% |
2021 Q2 | 28.32 Million USD | 0.0% |
2020 FY | 19.4 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AstraZeneca PLC | 100.97 Billion USD | 99.949% |
Bristol-Myers Squibb Company PFD CONV 2 | 95.15 Billion USD | 99.946% |
CSPC Pharmaceutical Group Limited | 6.52 Billion USD | 99.207% |
Novartis AG | 99.94 Billion USD | 99.948% |
PT Kalbe Farma Tbk. | 1.75 Billion USD | 97.06% |